home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

84 rows where docket_id = "FDA-2023-N-4225" sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_date, posted_month, comment_start_date, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

document_type 3

  • Supporting & Related Material 79
  • Other 3
  • Proposed Rule 2

posted_year 2

  • 2024 74
  • 2025 10

agency_id 1

  • FDA 84
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2023-N-4225-0133 FDA None FDA-2023-N-4225 Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products; Withdrawal Proposed Rule Withdrawal 2025-11-28T05:00:00Z 2025 11 2025-11-28T05:00:00Z   2025-11-28T19:47:58Z 2025-21407 0 0 09000064b90a1ed0
FDA-2023-N-4225-0099 FDA None FDA-2023-N-4225 Request for Extension from U.S. Chamber of Commerce Other Request for Extension 2025-03-21T04:00:00Z 2025 3 2025-03-21T04:00:00Z   2025-03-21T13:56:27Z   0 0 0900006486a08a9d
FDA-2023-N-4225-0100 FDA None FDA-2023-N-4225 Request for Extension from Essential Minerals Association Other Request for Extension 2025-03-21T04:00:00Z 2025 3 2025-03-21T04:00:00Z   2025-03-21T13:58:09Z   0 0 0900006486a0bb00
FDA-2023-N-4225-0083 FDA None FDA-2023-N-4225 Memorandum re Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products (Proposed Rule) Other Memorandum 2025-01-23T05:00:00Z 2025 1 2025-01-23T05:00:00Z   2025-01-23T20:44:28Z   0 0 09000064868f192c
FDA-2023-N-4225-0084 FDA None FDA-2023-N-4225 TAB A - Asbestos in Talc NPRM as Submitted to OMB Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:08Z   0 0 09000064868f10ef
FDA-2023-N-4225-0087 FDA None FDA-2023-N-4225 TAB B - Asbestos in Talc PRIA Track Changes Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:28Z   0 0 09000064868f10f2
FDA-2023-N-4225-0088 FDA None FDA-2023-N-4225 TAB C - Asbestos in Talc NPRM as Cleared by OMB Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:34Z   0 0 09000064868f10f3
FDA-2023-N-4225-0086 FDA None FDA-2023-N-4225 TAB B - Asbestos in Talc NPRM Track Changes Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:23Z   0 0 09000064868f10f1
FDA-2023-N-4225-0085 FDA None FDA-2023-N-4225 TAB A - Asbestos in Talc PRIA as Submitted to OMB Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:17Z   0 0 09000064868f10f0
FDA-2023-N-4225-0089 FDA None FDA-2023-N-4225 TAB C - Asbestos in Talc PRIA as Cleared by OMB Supporting & Related Material Background Material 2025-01-23T05:00:00Z 2025 1     2025-01-23T20:46:41Z   0 0 09000064868f10f4
FDA-2023-N-4225-0039 FDA None FDA-2023-N-4225 Reference 37 Rosner DG Nondetected The Politics of Measurem in Talc 1971 1976 AJPH Vol 2019 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:04Z   0 0 090000648688cadb
FDA-2023-N-4225-0046 FDA None FDA-2023-N-4225 PRIA Footnote Reference 1 Updating Value per Statistical Life (VSL) Estimates for Inflation and Changes in Real Income Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:46Z   0 0 090000648688cafa
FDA-2023-N-4225-0056 FDA None FDA-2023-N-4225 PRIA Reference 8 Passport Beauty and Personal Care in the US Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:50Z   0 0 090000648688cb05
FDA-2023-N-4225-0002 FDA None FDA-2023-N-4225 List of references 12 11 2024 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:21Z   0 0 090000648688caae
FDA-2023-N-4225-0028 FDA None FDA-2023-N-4225 Reference 26 - Lowers H -Tabulation of Asbestos Related Terminology 2002 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:58Z   0 0 090000648688cad1
FDA-2023-N-4225-0029 FDA None FDA-2023-N-4225 Reference 27 - Campbell WJ Selected Silicate Minerals and Their Asbestiform Varieties US Bureau of Mines Information Circular 8751- 1977 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:04Z   0 0 090000648688cad2
FDA-2023-N-4225-0043 FDA None FDA-2023-N-4225 Reference 41 USP-NF General Chapter Prospectus 1901_ Theory and Practices of Asbestos Detection in PHarmaceutical Talc 2021 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:29Z   0 0 090000648688cadf
FDA-2023-N-4225-0059 FDA None FDA-2023-N-4225 PRIA Reference 11 Malignant Mesothelioma and Its Non-Asbestos Causes Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:06Z   0 0 090000648688cb08
FDA-2023-N-4225-0018 FDA None FDA-2023-N-4225 Reference 16 Translocation of inhaled asbestos fibers from the lung to other tissues.pdf Suzuki Y 1991 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:54Z   0 0 090000648688cac8
FDA-2023-N-4225-0052 FDA None FDA-2023-N-4225 PRIA Reference 4 Method J 4-1 Asbestiform Amphibole Minerals in Cosmetic Talc Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:26Z   0 0 090000648688cb00
FDA-2023-N-4225-0054 FDA None FDA-2023-N-4225 PRIA Reference 6 White Paper IWGACP Scientific Opinions on Testing Methods for Asbestos in Cosmetic Products Containing Talc Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:39Z   0 0 090000648688cb03
FDA-2023-N-4225-0004 FDA None FDA-2023-N-4225 Reference 2 Where is Asbestos Found ATSDR - Naturally Occurring Asbestos Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:33Z   0 0 090000648688cab0
FDA-2023-N-4225-0019 FDA None FDA-2023-N-4225 Reference 17 Fitzgerald Comparing Historical and Recent Accelerated Concerns Regarding Asbestos in Talc 2021 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:00Z   0 0 090000648688cac9
FDA-2023-N-4225-0021 FDA None FDA-2023-N-4225 Reference 19 FDA In Brief_ FDA Releases Final Report of Talc-containing cosmetic products tested for asbestos Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:12Z   0 0 090000648688cacb
FDA-2023-N-4225-0051 FDA None FDA-2023-N-4225 PRIA Reference 3 Asbestos in Commercial Cosmetic Talcum Powder as a Cause of Mesothelioma in Women Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:21Z   0 0 090000648688caff
FDA-2023-N-4225-0053 FDA None FDA-2023-N-4225 PRIA Reference 5 The U.S. Pharmacopeial Convention Revision Bulletin Talc Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:32Z   0 0 090000648688cb01
FDA-2023-N-4225-0072 FDA None FDA-2023-N-4225 PRIA Reference 24 Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:17Z   0 0 090000648688cb18
FDA-2023-N-4225-0074 FDA None FDA-2023-N-4225 PRIA Reference 26 Some Pitfalls of Practical Benefit-Cost Analys Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:28Z   0 0 090000648688cb1a
FDA-2023-N-4225-0001 FDA None FDA-2023-N-4225 Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products Proposed Rule Notice of Proposed Rulemaking (NPRM) 2024-12-27T05:00:00Z 2024 12 2024-12-27T05:00:00Z 2025-03-28T03:59:59Z 2025-03-29T01:00:19Z 2024-30544 0 0 090000648689150a
FDA-2023-N-4225-0006 FDA None FDA-2023-N-4225 Reference 4 Segrave Overview of the Geology of Cosmetic Talc Formation 2021 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:45Z   0 0 090000648688cab2
FDA-2023-N-4225-0008 FDA None FDA-2023-N-4225 Reference 6 Toxicological Review of Libby Amphibole Asbestos EPA IRIS 2014 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:57Z   0 0 090000648688cab4
FDA-2023-N-4225-0010 FDA None FDA-2023-N-4225 Reference 8 Toxicological Profile for Asbestos ATSDR 2001 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:08Z   0 0 090000648688cab6
FDA-2023-N-4225-0023 FDA None FDA-2023-N-4225 Reference 21 Block Stimuli to the Revision Process Modernization of Asbestos Testing in Talc USP PF 40 4 2014 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:24Z   0 0 090000648688caba
FDA-2023-N-4225-0017 FDA None FDA-2023-N-4225 Reference 15 Asbestos exposure and ovarian fiber burden. Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:49Z   0 0 090000648688cac7
FDA-2023-N-4225-0041 FDA None FDA-2023-N-4225 Reference 39 USP CN Talc Detection of Asbestos in Pharmace Talc 1901 Theory and Practice of Asbestos Detection in Pharmace 2023.. Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:18Z   0 0 090000648688cadd
FDA-2023-N-4225-0049 FDA None FDA-2023-N-4225 PRIA Reference 1 National Toxicology Report on Carcinogens Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:10Z   0 0 090000648688cafd
FDA-2023-N-4225-0057 FDA None FDA-2023-N-4225 PRIA Reference 9 Talc and Pyrophyllite Mineral Commodity Summary Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:54Z   0 0 090000648688cb06
FDA-2023-N-4225-0061 FDA None FDA-2023-N-4225 PRIA Reference 13 Costs of Medical Care for Mesothelioma Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:17Z   0 0 090000648688cb0d
FDA-2023-N-4225-0064 FDA None FDA-2023-N-4225 PRIA Reference 16 Cost of Care for the Initial Management of Ovarian Cancer Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:34Z   0 0 090000648688cb10
FDA-2023-N-4225-0066 FDA None FDA-2023-N-4225 PRIA Reference 18 Guidelines for Regulatory Impact Analysis Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:45Z   0 0 090000648688cb12
FDA-2023-N-4225-0070 FDA None FDA-2023-N-4225 PRIA Reference 22 Douching and Genital Talc Use Patterns of Use and Reliability of Self-reported Exposure Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:06Z   0 0 090000648688cb16
FDA-2023-N-4225-0009 FDA None FDA-2023-N-4225 Reference 7 Filetti et al Update of in vitro in vivo and ex vivo fluoro edenite effects of malignant mesothelioma 2020 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:02Z   0 0 090000648688cab5
FDA-2023-N-4225-0015 FDA None FDA-2023-N-4225 Reference 13 IWGACP Appendices to White Paper January 13 2022 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:38Z   0 0 090000648688cac5
FDA-2023-N-4225-0067 FDA None FDA-2023-N-4225 PRIA Reference 19 USP's Iterative Approach to Standards Development and the Emerging Standards Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:50Z   0 0 090000648688cb13
FDA-2023-N-4225-0014 FDA None FDA-2023-N-4225 Reference 12 Asbestos hazards-and-safe-practice-for-clear-up-after-tsunami. 2006 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:33Z   0 0 090000648688cac4
FDA-2023-N-4225-0033 FDA None FDA-2023-N-4225 Reference 31 - COPYRIGHT International Organization for Standardization ISO 22262-1-2012 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:27Z   0 0 090000648688cad6
FDA-2023-N-4225-0036 FDA None FDA-2023-N-4225 Reference 34 - CIR Expert Panel Meeting March 18-19 2013 - Safety Assessment of Talc as Used in Cosmetics 2013 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:47Z   0 0 090000648688cad8
FDA-2023-N-4225-0045 FDA None FDA-2023-N-4225 Talc PRIA Reference List Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:41Z   0 0 090000648688caf9
FDA-2023-N-4225-0062 FDA None FDA-2023-N-4225 PRIA Reference 14 Lung Cancer Costs by Treatment Strategy and Phase of Care Among Patients Enrolled in Medicare Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:23Z   0 0 090000648688cb0e
FDA-2023-N-4225-0068 FDA None FDA-2023-N-4225 PRIA Reference 20 Consolidated Financial Statements and Report of Independent Certified Public Accountants United States Pharmacopeial Convention and Subsidia Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:56Z   0 0 090000648688cb14
FDA-2023-N-4225-0013 FDA None FDA-2023-N-4225 Reference 11 Asbestos - Overview _ Occupational Safety and Health Administration Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:27Z   0 0 090000648688cac3
FDA-2023-N-4225-0022 FDA None FDA-2023-N-4225 Reference 20 Millette Procedure for the Analysis of Talc for Asbestos 2015 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:18Z   0 0 090000648688cacc
FDA-2023-N-4225-0025 FDA None FDA-2023-N-4225 Reference 23 Peer review Report External Peer Review Comments and FDA Responses 2024 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:36Z   0 0 090000648688cace
FDA-2023-N-4225-0031 FDA None FDA-2023-N-4225 Reference 29 Baumann Asbestos is not just asbestos_ an unrecognised health hazard 2013 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:16Z   0 0 090000648688cad4
FDA-2023-N-4225-0037 FDA None FDA-2023-N-4225 Reference 35 Talc _ USP-NF Compendial Notices Intent to Revise Talc USP Monograph Asbestos Test Method 2020 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:52Z   0 0 090000648688cad9
FDA-2023-N-4225-0044 FDA None FDA-2023-N-4225 Reference 42 Preliminary Regulatory Impact Analysis Asbestos in Talc PRIA Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:35Z   0 0 090000648688caf8
FDA-2023-N-4225-0050 FDA None FDA-2023-N-4225 PRIA Reference 2 A Review of Human Carcinogens Part C Metals Arsenic Dusts and Fibres Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:16Z   0 0 090000648688cafe
FDA-2023-N-4225-0058 FDA None FDA-2023-N-4225 PRIA Reference 10 Asbestos Contamination in Talc-Based Cosmetics An Invisible Cancer Risk Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:00Z   0 0 090000648688cb07
FDA-2023-N-4225-0069 FDA None FDA-2023-N-4225 PRIA Reference 21 Sunscreen Drug Formulations for Over-the-Counter Human Use Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:01Z   0 0 090000648688cb15
FDA-2023-N-4225-0073 FDA None FDA-2023-N-4225 PRIA Reference 25 Perineal Use of Talc and Risk of Ovarian Cancer Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:23Z   0 0 090000648688cb19
FDA-2023-N-4225-0003 FDA None FDA-2023-N-4225 Reference 1 Ultramafic hosted talc magnesite deposits 2006 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:27Z   0 0 090000648688caaf
FDA-2023-N-4225-0011 FDA None FDA-2023-N-4225 Reference 9 IARC_Monograph_Asbestos.2012 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:14Z   0 0 090000648688cab7
FDA-2023-N-4225-0034 FDA None FDA-2023-N-4225 Reference 32 - International Organization for Standardization ISO 10312-2019 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:33Z   0 0 090000648688cabd
FDA-2023-N-4225-0027 FDA None FDA-2023-N-4225 Reference 25 Miller E. A review of the mesotheliogenic potency of cleavage fragments found in talc Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:52Z   0 0 090000648688cad0
FDA-2023-N-4225-0030 FDA None FDA-2023-N-4225 Reference 28 Van Gosen - A USGS Study of Talc Deposits and Associated Amphibole ....Southern Death Valley Region Californina 2004 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:09Z   0 0 090000648688cad3
FDA-2023-N-4225-0040 FDA None FDA-2023-N-4225 Reference 38 USP Talc Absence of Asbestos Test method Official May 1 2022 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:12Z   0 0 090000648688cadc
FDA-2023-N-4225-0042 FDA None FDA-2023-N-4225 Reference 40 General Chapter Prospectus 901_ Detection of Asbestos in Pharmaceutical Talc 2021 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:23Z   0 0 090000648688cade
FDA-2023-N-4225-0063 FDA None FDA-2023-N-4225 PRIA Reference 15 Treatment Survival and Costs of Laryngeal Cancer Care in the Elderly Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:28Z   0 0 090000648688cb0f
FDA-2023-N-4225-0065 FDA None FDA-2023-N-4225 PRIA Reference 17 Recall Cost Cast Studies Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:39Z   0 0 090000648688cb11
FDA-2023-N-4225-0071 FDA None FDA-2023-N-4225 PRIA Reference 23 The Environmental Injustice of Beauty Framing Chemical Exposures from Beauty Products as a Health Disparities Concern Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:56:12Z   0 0 090000648688cb17
FDA-2023-N-4225-0024 FDA None FDA-2023-N-4225 Reference 22 Interagency Workgroup for Asbestos in Consumer Products IWGACP- White Paper 2022 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:29Z   0 0 090000648688cacd
FDA-2023-N-4225-0026 FDA None FDA-2023-N-4225 Reference 24 Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:41Z   0 0 090000648688cacf
FDA-2023-N-4225-0038 FDA None FDA-2023-N-4225 Reference 36 ISO IEC Guide 2 2004. Standardization and related activities General vocabulary 2004 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:59Z   0 0 090000648688cada
FDA-2023-N-4225-0005 FDA None FDA-2023-N-4225 Reference 3 Virta Asbestos Geology Mineralogy Mining and Uses 2002 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:39Z   0 0 090000648688cab1
FDA-2023-N-4225-0007 FDA None FDA-2023-N-4225 Reference 5 Asbestos. In Report on Carcinogens Fiftheenth Edition 2021 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:49:51Z   0 0 090000648688cab3
FDA-2023-N-4225-0016 FDA None FDA-2023-N-4225 Reference 14 Ingested mineral fibers elimination in human urine Science 204 195-8 1979 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:44Z   0 0 090000648688cac6
FDA-2023-N-4225-0020 FDA None FDA-2023-N-4225 Reference 18 FDA Talc Previous Activity Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:51:06Z   0 0 090000648688caca
FDA-2023-N-4225-0035 FDA None FDA-2023-N-4225 Reference 33 IMA Amphibole Supergroup Mineral information data and localities Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:39Z   0 0 090000648688cad7
FDA-2023-N-4225-0048 FDA None FDA-2023-N-4225 PRIA Footnote Reference 3 A Population-level Approach to Distributional Weighting Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:57Z   0 0 090000648688cafc
FDA-2023-N-4225-0060 FDA None FDA-2023-N-4225 PRIA Reference 12 Under-Reporting of Adverse Drug Reactions A Systematic Review Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:55:12Z   0 0 090000648688cb09
FDA-2023-N-4225-0012 FDA None FDA-2023-N-4225 Reference 10 Asbestos Selected Cancers NAS 2006 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:50:20Z   0 0 090000648688cac2
FDA-2023-N-4225-0032 FDA None FDA-2023-N-4225 Reference 30 - National Institute for Occupational Safety and Health 2011 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:52:21Z   0 0 090000648688cad5
FDA-2023-N-4225-0047 FDA None FDA-2023-N-4225 PRIA Footnote Reference 2 Circular A-4 Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:53:52Z   0 0 090000648688cafb
FDA-2023-N-4225-0055 FDA None FDA-2023-N-4225 PRIA Reference 7 Latent Period for Malignant Mesothelioma of Occupational Origin Supporting & Related Material Background Material 2024-12-27T05:00:00Z 2024 12     2024-12-30T02:54:44Z   0 0 090000648688cb04

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 15.482ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API